Rational approaches to developing an anti-disease vaccine against malaria

Abstract

Vaccination against pathogen toxins provides a rational approach to prevent morbidity and mortality, and is widely validated in the context of bacterial infections. A saccharide-conjugate vaccine targeting the malaria glycosylphosphatidylinositol toxin glycan could therefore prevent severe disease. This strategy could also reduce the risk posed by 'rebound' infections or immunopathology associated with other interventions.